Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Gonadotropin-releasing hormone (GnRH) agonist (LHRH analog)

Leuprolide acetate

Lupron Depot

Dosage form
Tablet
Available strengths
3.75 mg (1-Month), 7.5 mg (1-Month), 11.25 mg (3-Month), 22.5 mg (3-Month), 30 mg (4-Month), 45 mg (6-Month)
Drug class
Gonadotropin-releasing hormone (GnRH) agonist (LHRH analog)
Common brand
Lupron Depot

Clinical overview. Leuprolide acetate (Lupron Depot) is a long-acting GnRH agonist injection given by a healthcare professional to suppress sex hormone production. It is used to treat advanced prostate cancer, central precocious puberty in children, endometriosis, and to shrink uterine fibroids before surgery. Common effects include hot flashes and injection site reactions, while serious risks include bone density loss, cardiovascular events, and mood changes.

Indication

Common therapeutic uses

  • Lupron Depot 7.5 mg (1-month), 22.5 mg (3-month), 30 mg (4-month), and 45 mg (6-month) are used to treat advanced prostate cancer.
  • Lupron Depot 3.75 mg (1-month) and 7.5 mg (1-month) are used to treat central precocious puberty in children.
  • Lupron Depot 3.75 mg (1-month) and 11.25 mg (3-month) are used to treat endometriosis, including pain relief and shrinking of endometriosis lesions, for up to six months, alone or combined with norethindrone acetate.
  • Lupron Depot 3.75 mg (1-month), combined with daily oral iron, is used before surgery to improve anemia caused by uterine fibroids.

Pregnancy

Risk assessment and monitoring considerations

Contraindicated in pregnancy. Confirm pregnancy status and discuss alternative therapy with the prescriber before dispensing.

  • Lupron Depot is contraindicated in women who are or may become pregnant.
  • Animal studies found a dose-related increase in major fetal abnormalities when leuprolide was given early in pregnancy in rabbits, though similar effects were not seen in rats.
  • Because leuprolide lowers sex hormone levels, spontaneous abortion may occur if the drug is given during pregnancy.
  • Pregnancy must be ruled out before starting treatment, and patients should use a non-hormonal method of contraception during therapy.
  • Patients who miss or delay a dose may ovulate and could become pregnant; anyone who becomes pregnant during treatment should stop Lupron Depot and consult their physician.

Breastfeeding

Infant exposure considerations

  • It is not known whether leuprolide passes into breast milk, so Lupron Depot is contraindicated while breastfeeding.

Geriatrics

Dosing and tolerability considerations

  • Most participants in prostate cancer clinical trials were 65 years of age or older, and Lupron Depot's established dosing for that indication reflects this population.
  • Lupron Depot 3.75 mg (1-month) and 11.25 mg (3-month) for endometriosis have not been studied in women over 65 and are not indicated in this age group.

Pediatrics

Use in children and adolescents

  • Lupron Depot 3.75 mg, 7.5 mg, 11.25 mg, and 15 mg (1-month) are approved for central precocious puberty in children, with the strength based on the child's body weight.
  • Lupron Depot 22.5 mg (3-month), 11.25 mg (3-month), and 30 mg (4-month) have not been studied in children and are not established for pediatric use outside central precocious puberty dosing.
  • Use of the 3.75 mg (1-month) strength for endometriosis or uterine fibroids has only been studied in women 18 years of age and older.

Dosage & Administration

Practical dosing and administration

  • For central precocious puberty, the starting dose is 0.3 mg/kg every 4 weeks (minimum 7.5 mg) given as a single intramuscular injection, with the exact strength (7.5 mg, 11.25 mg, or 15 mg) determined by the child's body weight.
  • If a child's puberty is not fully suppressed, the dose can be increased in 3.75 mg increments every 4 weeks up to a maximum of 15 mg per month.
  • For prostate cancer, the recommended dose is 7.5 mg by intramuscular injection once a month, or alternatively 22.5 mg every 3 months, 30 mg every 4 months, or 45 mg every 6 months, depending on the formulation chosen.
  • For endometriosis, the dose is 3.75 mg by intramuscular injection once a month or 11.25 mg once every 3 months, usually for an initial six-month course, alone or combined with norethindrone acetate 5 mg daily.
  • For uterine fibroids, the dose is 3.75 mg by intramuscular injection once a month, combined with daily oral iron therapy, for up to three months before surgery.
  • Different depot formulations (1-month, 3-month, 4-month, 6-month) are not interchangeable at fractional doses, because of their different release characteristics.
  • Lupron Depot must be reconstituted with its supplied diluent immediately before injection and used right away, since the suspension settles quickly and contains no preservative.
  • Missing a scheduled injection by a few days is not expected to disrupt treatment benefit for prostate cancer, endometriosis, or uterine fibroids, but a missed or delayed dose in central precocious puberty can allow puberty to resume and should be avoided.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • There is no clinical experience with acute overdose of leuprolide acetate in humans.
  • Because its acute toxicity in animal studies is low, significant adverse effects are not expected from an accidental extra dose.
  • Very high-dose animal studies showed only difficulty breathing, decreased activity, and injection-site irritation, with no clear human counterpart identified.
  • In cases of suspected overdose, treatment is symptomatic and supportive, with close patient monitoring.

Common side effects

Frequently reported tolerability concerns

  • Hot flashes and sweating are very common with Lupron Depot, reflecting the drop in sex hormone levels.
  • General aches and pains may occur.
  • Fatigue (asthenia) may occur.
  • Headache may occur.
  • Injection site reactions, such as pain or swelling, may occur.
  • Nausea or vomiting may occur.
  • Swelling (edema) may occur.
  • Joint pain or joint disorders may occur.
  • Dizziness or vertigo may occur.
  • Insomnia or other sleep disturbances may occur.
  • Testicular shrinkage and impotence may occur in men, reflecting reduced testosterone.
  • Menstrual irregularities, including breakthrough bleeding, may occur in women.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Lupron Depot can cause severe allergic reactions, including anaphylaxis.
  • Rare but serious skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported.
  • Seizures have been reported, including in people with no prior seizure history.
  • Pseudotumor cerebri (increased pressure around the brain) has been reported, particularly in children, and can cause headache, vision changes, or vomiting.
  • Pituitary apoplexy, a rare but serious event caused by sudden bleeding or loss of blood supply to the pituitary gland, has been reported, most often within the first two weeks of treatment.
  • Serious liver injury, including fatal cases, has been reported.
  • Loss of bone density can occur with long-term use, increasing the risk of osteoporosis and fractures.
  • In men being treated for prostate cancer, an initial testosterone surge can temporarily worsen bone pain, and in rare cases cause spinal cord compression, urinary tract obstruction, or new neurological symptoms.
  • An increased risk of heart attack, sudden cardiac death, and stroke has been reported in men receiving GnRH agonists.
  • Lupron Depot can prolong the heart's QT interval, which may increase the risk of dangerous heart rhythm problems, especially when combined with other QT-prolonging drugs.
  • New or worsening diabetes and other metabolic changes, such as high cholesterol or fatty liver disease, may occur.
  • Mood changes, including irritability, anger, and worsening depression, have been reported, along with rare reports of suicidal thoughts or attempts.
  • Serious blood clots, including deep vein thrombosis, pulmonary embolism, heart attack, and stroke, have been reported in women treated for endometriosis or uterine fibroids.
  • Skin necrosis (tissue death) at the injection site has been reported.
  • Interstitial lung disease and pulmonary fibrosis have been reported.
  • Seek urgent medical attention for sudden severe headache, vision changes, chest pain, signs of a stroke, severe allergic reaction, or new weakness or numbness in the legs.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients or families with a history of osteoporosis, or those using long-term corticosteroids or anticonvulsants, or with heavy alcohol or tobacco use, because of the added risk of bone loss.
  • Use with caution in men with a history of heart disease, diabetes, or other cardiovascular risk factors, given the increased cardiovascular risk with GnRH agonist therapy.
  • Use with caution in patients with congenital long QT syndrome, electrolyte imbalances, heart failure, or those taking other QT-prolonging medications.
  • Use with caution in men with spread of cancer to the spine or significant urinary tract obstruction, who should begin therapy under close medical supervision because of the risk of worsening symptoms in the first weeks of treatment.
  • Use with caution in patients with a history of seizures, epilepsy, brain tumors, or other central nervous system conditions, and in those taking other medications associated with seizures.
  • Use with caution in patients with diabetes or risk factors for diabetes, who should have periodic blood glucose monitoring.
  • Use with caution in patients with a personal or family history of depression or other psychiatric illness, given reports of mood changes and rare suicidal ideation.
  • Use with caution in patients with pre-existing asthma, sinusitis, or drug allergies, who may be at higher risk of hypersensitivity-type reactions.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with known hypersensitivity to leuprolide acetate, other GnRH agonists, similar peptide hormones, or any component of the syringe.
  • Contraindicated in women who are or may become pregnant.
  • Contraindicated during breastfeeding.
  • Contraindicated in patients with undiagnosed abnormal vaginal bleeding when used for uterine fibroids or endometriosis.

Drug interactions

Clinically relevant combinations

  • Leuprolide acetate is not broken down by the liver's cytochrome P450 enzyme system, so classic drug-metabolism interactions are not expected.
  • Combining Lupron Depot with other medications that prolong the QT interval, such as certain antiarrhythmics (e.g., quinidine, amiodarone, sotalol, flecainide), certain antipsychotics, certain antidepressants, methadone, certain macrolide or quinolone antibiotics, antimalarials, azole antifungals, ondansetron, or salbutamol, requires careful evaluation because of an increased risk of dangerous heart rhythm changes.
  • No formal drug-drug interaction studies have been conducted with leuprolide acetate.
  • For patients using Lupron Depot with norethindrone acetate for endometriosis, refer to norethindrone acetate's own product information for its specific interactions.
  • Lupron Depot temporarily alters pituitary-gonadal hormone testing, so diagnostic hormone tests performed during or shortly after treatment may give misleading results.

Food interactions

Meal-related administration

  • Lupron Depot is given by intramuscular injection rather than swallowed, so it can be administered without regard to meals; food does not affect its absorption or effectiveness.

Time of administration

Practical scheduling

  • Lupron Depot injections are given by a healthcare professional on a fixed schedule (monthly, or every 3, 4, or 6 months depending on the formulation) and are not affected by time of day or meals.
  • Try to keep injection appointments as close to the scheduled date as possible, since delaying a dose can reduce hormone suppression and, in children being treated for central precocious puberty, can allow puberty to resume.

Storage

Product handling

  • Store Lupron Depot syringes at room temperature between 15°C and 25°C, and protect from freezing.
  • Once reconstituted, the suspension must be used immediately, since it contains no preservative and settles quickly.
  • Keep out of the reach and sight of children.

Patient take-away

Key counselling points for a quick closing summary

  • Lupron Depot is a long-acting hormone therapy given as an injection by a healthcare professional, not a medication taken at home.
  • Hormone levels rise briefly in the first weeks of treatment before falling to the desired suppressed level, so symptoms may temporarily worsen during this time.
  • Keep every scheduled injection appointment, since delaying a dose can reduce the treatment's effectiveness.
  • Tell your healthcare provider about any new bone pain, mood changes, vision changes, severe headache, leg weakness, or signs of an allergic reaction.
  • If being treated for prostate cancer, tell your doctor about any heart disease, diabetes, or medications that affect heart rhythm.
  • If being treated for endometriosis or uterine fibroids, use a non-hormonal method of contraception during treatment and tell your doctor right away if pregnancy is suspected.

References

Source material and product information

  1. Health Canada Product Monograph — Leuprolide acetate

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.